Login Register Cart 0
Generic placeholder image

Current Medical Imaging

Editor-in-Chief

ISSN (Print): 1573-4056
ISSN (Online): 1875-6603

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Feasibility of Imaging-Based Quantitative Hepatic Function Assessment: Gd-EOB-DTPA-Enhanced Liver MR Imaging Combined with T1 Mapping

Author(s): Zhi Dong, Meng Wang, Yanqing Feng, Huasong Cai, Shi-Ting Feng, Zi-Ping Li, Zhi Lin and Zhenpeng Peng*

Volume 19, Issue 12, 2023

Published on: 02 February, 2023

Article ID: e130123212716 Pages: 10

DOI: 10.2174/1573405619666230113115748

Price: $65

Abstract

Objective: to investigate the feasibility of gadoxetic acid (Gd-EOB-DTPA) enhanced MRI combined with T1 mapping in quantitative hepatic function assessment.

Methods: this study retrospectively enrolled 94 patients with Gd-EOB-DTPA enhanced MRI combined with T1 mapping, divided into group A (grade A, n=73), group B (grade B, n=14) and group C (grade C, n=7) based on Child-Pugh classification. Liver T1 relaxation times on plain scan (T1P) and hepatocellular phase (T1E) were measured. Decrease in T1 (T1D) and the percentage of decrease in T1 (T1D%) were calculated as follows: T1D=T1P-T1E, T1D%= T1D/T1P×100%. The relationship between T1P, T1E, T1D, T1D% and liver function classification was analyzed.

Results: T1P, T1D, and T1D% in group A were significantly higher than those of group B and C. T1E in group A was lower than those of group B and C. T1D% was significantly different between group B and C. There was no significant difference in T1P, T1E, T1D between groups B and C. T1E was positively correlated with liver function levels, T1P and T1D had a negative correlation with liver function levels. T1P, T1E, T1D, T1D% were significantly different between cirrhotic and non-cirrhotic groups. T1D% of less than 70% suggests liver dysfunction.

Conclusion: Gd-EOB-DTPA enhanced liver MRI combined with T1 mapping is feasible for quantitative assessment of hepatic function.

Graphical Abstract

[1]
Wang LJ, Yan XL, Li J, Wang K, Xing BC. Indocyanine green clearance test for the preoperative assessment of chemotherapy-related hepatic injury in patients with colorectal liver metastasis. Cancer Manag Res 2020; 12: 3237-45.
[http://dx.doi.org/10.2147/CMAR.S252693] [PMID: 32440220]
[2]
Bora A, Alptekin C, Yavuz A, Batur A, Akdemir Z, Berköz M. Assessment of liver volume with computed tomography and comparison of findings with ultrasonography. Abdom Imag 2014; 39(6): 1153-61.
[http://dx.doi.org/10.1007/s00261-014-0146-5] [PMID: 24777593]
[3]
Manka P, Canbay A, Bechmann LP. Model for end-stage liver disease-sodium in acute-on-chronic liver failure. J Hepatol 2020; 73(6): 1425-33.
[4]
Nadim MK, DiNorcia J, Ji L, et al. Inequity in organ allocation for patients awaiting liver transplantation: Rationale for uncapping the model for end-stage liver disease. J Hepatol 2017; 67(3): 517-25.
[http://dx.doi.org/10.1016/j.jhep.2017.04.022] [PMID: 28483678]
[5]
Fan ST. Liver functional reserve estimation: State of the art and relevance for local treatments. J Hepatobiliary Pancreat Sci 2010; 17(4): 380-4.
[http://dx.doi.org/10.1007/s00534-009-0229-9] [PMID: 19865790]
[6]
Kokudo T, Hasegawa K, Shirata C, et al. Assessment of preoperative liver function for surgical decision making in patients with hepatocellular carcinoma. Liver Cancer 2019; 8(6): 447-56.
[http://dx.doi.org/10.1159/000501368] [PMID: 31799202]
[7]
Lock JF, Malinowski M, Seehofer D, et al. Function and volume recovery after partial hepatectomy: Influence of preoperative liver function, residual liver volume, and obesity. Langenbecks Arch Surg 2012; 397(8): 1297-304.
[http://dx.doi.org/10.1007/s00423-012-0972-2] [PMID: 22729717]
[8]
Shimizu J, Dono K, Gotoh M, et al. Evaluation of regional liver function by gadolinium-EOB-DTPA-enhanced MR imaging. Dig Dis Sci 1999; 44(7): 1330-7.
[http://dx.doi.org/10.1023/A:1026679113772] [PMID: 10489914]
[9]
Yoon JH, Choi JI, Jeong YY, et al. Pre-treatment estimation of future remnant liver function using gadoxetic acid MRI in patients with HCC. J Hepatol 2016; 65(6): 1155-62.
[http://dx.doi.org/10.1016/j.jhep.2016.07.024] [PMID: 27476767]
[10]
Dahlqvist Leinhard O, Dahlström N, Kihlberg J, et al. Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: A pilot study. Eur Radiol 2012; 22(3): 642-53.
[http://dx.doi.org/10.1007/s00330-011-2302-4] [PMID: 21984449]
[11]
Kim JE, Kim HO, Bae K, Choi DS, Nickel D. T1 mapping for liver function evaluation in gadoxetic acid–enhanced MR imaging: Comparison of look-locker inversion recovery and B1 inhomogeneity–corrected variable flip angle method. Eur Radiol 2019; 29(7): 3584-94.
[http://dx.doi.org/10.1007/s00330-018-5947-4] [PMID: 30903328]
[12]
Hoffman DH, Ayoola A, Nickel D, et al. MR elastography, T1 and T2 relaxometry of liver: Role in noninvasive assessment of liver function and portal hypertension. Abdom Radiol (NY) 2020; 45(9): 2680-7.
[http://dx.doi.org/10.1007/s00261-020-02432-7] [PMID: 32274552]
[13]
Motosugi U, Ichikawa T, Sou H, et al. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: Which biological markers of the liver function affect the enhancement? J Magn Reson Imaging 2009; 30(5): 1042-6.
[http://dx.doi.org/10.1002/jmri.21956] [PMID: 19856436]
[14]
Paes-Barbosa FC, Ferreira FG, Szutan LA. Hepatectomy preoperative planning. Rev Col Bras Cir 2010; 37(5): 370-5.
[http://dx.doi.org/10.1590/S0100-69912010000500011] [PMID: 21181004]
[15]
Dyk P, Weiner A, Badiyan S, Myerson R, Parikh P, Olsen J. Effect of high-dose stereotactic body radiation therapy on liver function in the treatment of primary and metastatic liver malignancies using the Child-Pugh score classification system. Pract Radiat Oncol 2015; 5(3): 176-82.
[http://dx.doi.org/10.1016/j.prro.2014.09.007] [PMID: 25423889]
[16]
Okuaki T, Takayama Y, Nishie A, et al. T 1ρ mapping improvement using stretched-type adiabatic locking pulses for assessment of human liver function at 3 T. Magn Reson Imaging 2017; 40: 17-23.
[http://dx.doi.org/10.1016/j.mri.2017.03.006] [PMID: 28363761]
[17]
Steelandt J, Jean-Bart E, Goutelle S, Tod M. A prediction model of drug exposure in cirrhotic patients according to child–pugh classification. Clin Pharmacokinet 2015; 54(12): 1245-58.
[http://dx.doi.org/10.1007/s40262-015-0288-9] [PMID: 26070946]
[18]
Gschwend S, Ebert W, Schultze-Mosgau M, Breuer J. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment. Invest Radiol 2011; 46(9): 556-66.
[http://dx.doi.org/10.1097/RLI.0b013e31821a218a] [PMID: 21623212]
[19]
Yoneda N, Matsui O, Kitao A, et al. Benign hepatocellular nodules: Hepatobiliary phase of gadoxetic acid–enhanced MR imaging based on molecular background. Radiographics 2016; 36(7): 2010-27.
[http://dx.doi.org/10.1148/rg.2016160037] [PMID: 27740898]
[20]
Motosugi U, Bannas P, Sano K, Reeder SB. Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma. J Magn Reson Imaging 2015; 41(2): 251-65.
[http://dx.doi.org/10.1002/jmri.24712] [PMID: 25104398]
[21]
Wu JW, Yu YC, Qu XL, Zhang Y, Gao H. Optimization of hepatobiliary phase delay time of Gd-EOB-DTPA-enhanced magnetic resonance imaging for identification of hepatocellular carcinoma in patients with cirrhosis of different degrees of severity. World J Gastroenterol 2018; 24(3): 415-23.
[http://dx.doi.org/10.3748/wjg.v24.i3.415] [PMID: 29391764]
[22]
Liang M, Zhao J, Xie B, et al. MR liver imaging with Gd-EOB-DTPA: The need for different delay times of the hepatobiliary phase in patients with different liver function. Eur J Radiol 2016; 85(3): 546-52.
[http://dx.doi.org/10.1016/j.ejrad.2015.12.015] [PMID: 26860666]
[23]
Sciarra A, Schmidt S, Pellegrinelli A, et al. OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd-EOB-DTPA uptake and correlates with risk of malignancy. Liver Int 2019; 39(1): 158-67.
[http://dx.doi.org/10.1111/liv.13964] [PMID: 30218633]
[24]
Yoneda N, Matsui O, Ikeno H, et al. Correlation between Gd-EOB-DTPA-enhanced MR imaging findings and OATP1B3 expression in chemotherapy-associated sinusoidal obstruction syndrome. Abdom Imaging 2015; 40(8): 3099-103.
[http://dx.doi.org/10.1007/s00261-015-0503-z] [PMID: 26187715]
[25]
Ueno A, Masugi Y, Yamazaki K, et al. OATP1B3 expression is strongly associated with Wnt/β-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma. J Hepatol 2014; 61(5): 1080-7.
[http://dx.doi.org/10.1016/j.jhep.2014.06.008] [PMID: 24946283]
[26]
Wu MR, Liu HM, Lu CW, et al. Organic anion‐transporting polypeptide 1B3 as a dual reporter gene for fluorescence and magnetic resonance imaging. FASEB J 2018; 32(3): 1705-15.
[http://dx.doi.org/10.1096/fj.201700767R] [PMID: 29146731]
[27]
Obmann VC, Catucci D, Berzigotti A, et al. T1 reduction rate with Gd-EOB-DTPA determines liver function on both 1.5 T and 3 T MRI. Sci Rep 2022; 12(1): 4716.
[http://dx.doi.org/10.1038/s41598-022-08659-2] [PMID: 35304554]
[28]
Kim KA, Park MS, Kim IS, et al. Quantitative evaluation of liver cirrhosis using T1 relaxation time with 3 tesla MRI before and after oxygen inhalation. J Magn Reson Imaging 2012; 36(2): 405-10.
[http://dx.doi.org/10.1002/jmri.23620] [PMID: 22392835]
[29]
Heye T, Yang SR, Bock M, et al. MR relaxometry of the liver: Significant elevation of T1 relaxation time in patients with liver cirrhosis. Eur Radiol 2012; 22(6): 1224-32.
[http://dx.doi.org/10.1007/s00330-012-2378-5] [PMID: 22302503]
[30]
Hoad CL, Palaniyappan N, Kaye P, et al. A study of T1 relaxation time as a measure of liver fibrosis and the influence of confounding histological factors. NMR Biomed 2015; 28(6): 706-14.
[http://dx.doi.org/10.1002/nbm.3299] [PMID: 25908098]
[31]
Zhou ZP, Long LL, Qiu WJ, et al. Evaluating segmental liver function using T1 mapping on Gd-EOB-DTPA-enhanced MRI with a 3.0 Tesla. BMC Med Imaging 2017; 17(1): 20.
[http://dx.doi.org/10.1186/s12880-017-0192-x] [PMID: 28249571]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy